| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNLR1 |
| Uniprot No | Q8IU57 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-228aa |
| 氨基酸序列 | RPRLAPPQNVTLLSQNFSVYLTWLPGLGNPQDVTYFVAYQSSPTRRRWREVEECAGTKELLCSMMCLKKQDLYNKFKGRVRTVSPSSKSPWVESEYLDYLFEVEPAPPVLVLTQTEEILSANATYQLPPCMPPLDLKYEVAFWKEGAGNKTLFPVTPHGQPVQITLQPAASEHHCLSARTIYTFSVPKYSKFSKPTCFLLEVPEANWA |
| 预测分子量 | 27.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNLR1重组蛋白的3篇参考文献示例(注：内容为虚构模拟，仅供参考)：
1. **文献名称**：*Crystal Structure of Human IFNLR1 Reveals Ligand Binding Specificity*
**作者**：Zhang Y, et al.
**摘要**：本研究解析了IFNLR1重组蛋白的晶体结构，揭示了其与III型干扰素(IFN-λ)结合的分子机制，为设计靶向该受体的抗病毒药物提供了结构基础。
2. **文献名称**：*Functional Characterization of Recombinant IFNLR1 in Antiviral Signaling Pathways*
**作者**：Tanaka K, et al.
**摘要**：通过体外表达IFNLR1重组蛋白，证明其与IL10RB亚基形成复合物后激活JAK-STAT通路，显著增强宿主细胞对RNA病毒的防御能力。
3. **文献名称**：*High-Yield Production of Biologically Active IFNLR1 in Mammalian Cells*
**作者**：Chen L, et al.
**摘要**：开发了一种基于HEK293细胞的重组IFNLR1蛋白表达系统，纯化后的蛋白在细胞模型中有效诱导干扰素刺激基因(ISGs)的表达，适用于治疗性研究。
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“IFNLR1 recombinant protein”或“IFNLR1 structure/function”。
**Background of IFNLR1 Recombinant Protein**
IFNLR1 (Interferon Lambda Receptor 1), also known as IL-28RA, is a key component of the type III interferon (IFN-λ) signaling pathway. It belongs to the class II cytokine receptor family and pairs with the IL10Rβ subunit to form a functional receptor complex for IFN-λs (IFN-λ1. IFN-λ2. IFN-λ3. and IFN-λ4). This receptor is predominantly expressed on epithelial cells and specific immune cells, contributing to tissue-specific antiviral and immunomodulatory responses. Unlike the ubiquitously expressed type I interferon receptor (IFNAR), IFNLR1’s restricted cellular distribution allows IFN-λ to target mucosal surfaces and barrier tissues, minimizing systemic inflammation.
Recombinant IFNLR1 protein is engineered to mimic the extracellular domain of the native receptor, often produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. It is purified via affinity chromatography and validated for binding activity using techniques like surface plasmon resonance (SPR) or ELISA.
Research applications include studying IFN-λ signaling mechanisms, viral pathogenesis (e.g., hepatitis, influenza), and autoimmune disorders. IFNLR1 recombinant protein can act as a decoy receptor to neutralize IFN-λ activity, offering therapeutic potential in conditions driven by excessive interferon signaling. Additionally, it aids in structural studies to elucidate receptor-ligand interactions and design targeted therapies.
The development of IFNLR1-based tools underscores its importance in balancing antiviral defense and immune tolerance, highlighting its emerging role in precision medicine for infections, cancer, and inflammatory diseases.
×
